CTLA4 and infection: The use of abatacept and belatacept in CTLA-4 haploinsufficiency and LRBA deficiency appears to be a promising first line therapy to control manifestations of immune dysregulation, however, the lifelong use of this therapy is limited by increased susceptibility to infections and possible evolution of malignancies (54).